Artelo Biosciences Company Leadership
| ARTL Stock | USD 1.32 0.04 3.13% |
Artelo Biosciences employs about 6 people. The company is managed by 9 executives with a total tenure of roughly 90 years, averaging almost 10.0 years of service per executive, having 0.67 employees per reported executive. Inspection of Artelo Biosciences' management performance can provide insight into the company performance.
| David Jeffreys Chairman Non-Executive Chairman of the Board |
Artelo |
Artelo Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.3709) % which means that it has lost $0.3709 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5963) %, meaning that it created substantial loss on money invested by shareholders. Artelo Biosciences' management efficiency ratios could be used to measure how well Artelo Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.51. Return On Capital Employed is expected to rise to -0.58 this year. At this time, Artelo Biosciences' Intangibles To Total Assets are quite stable compared to the past year. Debt To Assets is expected to rise to 0.01 this year, although the value of Non Current Assets Total will most likely fall to about 1.5 M.Common Stock Shares Outstanding is expected to rise to about 3.4 M this year, although the value of Net Loss is projected to rise to (6.4 M).
Artelo Biosciences Workforce Comparison
Artelo Biosciences is rated below average in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 4,670. Artelo Biosciences adds roughly 6.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Artelo Biosciences Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Artelo Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Artelo Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Artelo Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Matsui Connie few days ago Disposition of 1083 shares by Matsui Connie of Artelo Biosciences at 2.01 subject to Rule 16b-3 | ||
Matsui Connie over a week ago Disposition of 667 shares by Matsui Connie of Artelo Biosciences at 15.0 subject to Rule 16b-3 | ||
Kelly Steven over a month ago Acquisition by Kelly Steven of 667 shares of Artelo Biosciences at 1.55 subject to Rule 16b-3 | ||
Matsui Connie over a month ago Disposition of 1083 shares by Matsui Connie of Artelo Biosciences at 2.01 subject to Rule 16b-3 | ||
Blayney Douglas over six months ago Acquisition by Blayney Douglas of 1083 shares of Artelo Biosciences subject to Rule 16b-3 | ||
Blayney Douglas over six months ago Acquisition by Blayney Douglas of 667 shares of Artelo Biosciences subject to Rule 16b-3 | ||
Gorgas Gregory D over a year ago Acquisition by Gorgas Gregory D of 85000 shares of Artelo Biosciences subject to Rule 16b-3 |
Artelo Biosciences Notable Stakeholders
An Artelo Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Artelo Biosciences often face trade-offs trying to please all of them. Artelo Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Artelo Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| David Jeffreys | Non-Executive Chairman of the Board | Profile | |
| Phillip Rose | Non-Executive Director | Profile | |
| Serena Tremlett | Non-Executive Director | Profile | |
| Roddy Sage | Non-Executive Director | Profile | |
| Jeff Chowdhry | Non-Executive Director | Profile | |
| Jason Baybutt | Senior Finance | Profile | |
| Andrew Yates | Senior Officer | Profile | |
| Steven Reich | Chief Officer | Profile | |
| Gregory MBA | CEO and President | Profile |
About Artelo Biosciences Management Performance
The success or failure of an entity such as Artelo Biosciences often depends on how effective the management is. Artelo Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Artelo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Artelo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.48) | (0.51) | |
| Return On Capital Employed | (0.61) | (0.58) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.59) | (0.56) |
The data published in Artelo Biosciences' official financial statements usually reflect Artelo Biosciences' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Artelo Biosciences. For example, before you start analyzing numbers published by Artelo accountants, it's critical to develop an understanding of what Artelo Biosciences' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Artelo Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Artelo Biosciences' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Artelo Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Artelo Biosciences. Please utilize our Beneish M Score to check the likelihood of Artelo Biosciences' management manipulating its earnings.
Artelo Biosciences Workforce Analysis
Traditionally, organizations such as Artelo Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Artelo Biosciences within its industry.Artelo Biosciences Manpower Efficiency
Return on Artelo Biosciences Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.7M | |
| Net Loss Per Executive | 1.1M | |
| Working Capital Per Employee | 1.6M | |
| Working Capital Per Executive | 1.1M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artelo Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Artelo Stock analysis
When running Artelo Biosciences' price analysis, check to measure Artelo Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artelo Biosciences is operating at the current time. Most of Artelo Biosciences' value examination focuses on studying past and present price action to predict the probability of Artelo Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artelo Biosciences' price. Additionally, you may evaluate how the addition of Artelo Biosciences to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |
Is Artelo Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.14) | Return On Assets (0.37) | Return On Equity (0.60) |
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Artelo Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.